Purchase will allow Nexus to offer products for biochemical, cell-based, and genomic screening applications.!--h2>
Nexus Biosystems acquired Aurora Biotechnologies, thus expanding into high-throughput biochemical, cell-based, and genomic screening applications. The company has traditionally provided technologies and automated sample-management systems to pharmaceutical, biotech, agrichemical, and research institutions.
Aurora serves the discovery research markets with consumable microplate products that enable high-throughput analysis of chemical compounds and cellular assays. Its offerings include a range of high-performance microplate designs including 1,536- and 3,456-well plates.
“Aurora’s legacy in understanding key processes in assay technologies and consumables is a great fit with the Nexus sample-management and sample-processing technologies,” Peter Coassin, president and chief technical officer of Aurora.